Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease

Journal of the American Society of Nephrology

Volumn 27, Issue 1, 2016, Pages 256-264

  Lenders, Malte ^a   Stypmann, Jörg ^a   Duning, Thomas ^a   Schmitz, Boris ^a   Brand, Stefan Martin ^a   Brand, Eva ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; ALPHA GALACTOSIDASE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; IMMUNOMODULATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NONSENSE MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; BLOOD; MIDDLE AGED; TREATMENT FAILURE;

ADULT; ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84954458962     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014121226     Document Type: Article

References (25)

1. Zarate YA, Hopkin RJ: Fabry's disease. Lancet 372: 1427-1435, 2008
2. Eng CM,GuffonN, WilcoxWR,Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16, 2001
3. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285: 2743-2749, 2001
4. Linthorst GE, Hollak CEM, Donker-Koopman WE, Strijland A, Aerts JMFG: Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66: 1589-1595, 2004
5. Bénichou B, Goyal S, Sung C, Norfleet AM, O'Brien F: A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 96: 4-12, 2009
6. Hollak CEM, Linthorst GE: Immune response to enzyme replacement therapy in Fabry disease: Impact on clinical outcome? Mol Genet Metab 96: 1-3, 2009
7. Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S,Wijburg FA, Hollak CE, Linthorst GE: Long-term effect of antibodies against infused alphagalactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE 7: E47805, 2012
8. Lang RM, BierigM,Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group-American Society of Echocardiography's Guidelines and Standards CommitteeEuropean Association of Echocardiography: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J AmSoc Echocardiogr 18: 1440-1463, 2005
9. Kidney DiseaseImproving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3[Suppl]: 1-150, 2013
10. Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, Beitner-Johnson D, Cizmarik M, Cole JA, Kingma W, Warnock DG: Anti-a-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry. Mol Genet Metab 105: 443-449, 2012
11. Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E: Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24: 137-148, 2013
12. WarnockDG,Mauer M: Fabry disease: Dosematters.JAmSocNephrol 25: 653-655, 2014
13. Weidemann F, Krämer J, Duning T, LendersM,Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM,Wanner C, Brand E: Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 25: 837-849, 2014
14. Schellekens H. The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. Clin Ther 30 Suppl B: S50-S51, 2008
15. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, Barton NW: Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. Pediatrics 100: E11, 1997
16. RosenbergM, KingmaW, FitzpatrickMA, RichardsSM: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93: 2081-2088, 1999
17. Markic J, Polic B, Kuzmanic-Samija R, Marusic E, Stricevic L, Metlicic V, Mestrovic J: Immune modulation therapy in a CRIM-positive and IgG antibody-positive infantwith Pompe disease treatedwith alglucosidase alpha: A case report. JIMD Rep 2: 11-15, 2012
18. Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter GJ, Özkan L, Plug I, Grinberg D, Vilageliu L, Halley DJ, van der Ploeg AT, Reuser AJ: Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis 8: 51, 2013
19. Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, Picard MH, Polk DM, Ragosta M, Ward RP, Weiner RB; American College of Cardiology Foundation Appropriate Use Criteria Task Force-American Society of Echocardiography; American Heart Association; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Critical Care Medicine; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance: ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsedby theAmericanCollege ofChest Physicians. JAmCollCardiol 57: 1126-1166, 2011
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
21. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKDEPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367: 20-29, 2012
22. Whybra C, Kampmann C, Krummenauer F, RiesM,Mengel E,Miebach E, Baehner F, KimK, BajboujM, Schwarting A,Gal A, BeckM: TheMainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65: 299-307, 2004
23. Giannini EH,Mehta AB, HilzMJ, BeckM, BichetDG, Brady RO,West M, Germain DP, Wanner C, Waldek S, Clarke JT,Mengel E, Strotmann JM, Warnock DG, Linhart A: A validated disease severity scoring system for Fabry disease. Mol Genet Metab 99: 283-290, 2010
24. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W: Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab ClinMed 81: 157-171, 1973
25. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML: Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 112: 247-251, 1981